Business Description
Gentian Diagnostics AS
ISIN : NO0010748866
Total Employee Number:
64Compare
Compare
Traded in other countries / regions
GENT.NorwayGENTOo.Sweden6FK.Germany IPO Date
2016-12-14Description
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.19 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 10.32 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 7.26 | |||||
Beneish M-Score | -3.26 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 20 | |||||
3-Year Book Growth Rate | 10 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 89.96 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.55 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.36 | |||||
9-Day RSI | 49.94 | |||||
14-Day RSI | 49.7 | |||||
3-1 Month Momentum % | -3.33 | |||||
6-1 Month Momentum % | -34.09 | |||||
12-1 Month Momentum % | -39.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.7 | |||||
Quick Ratio | 4.01 | |||||
Cash Ratio | 2.82 | |||||
Days Inventory | 233.65 | |||||
Days Sales Outstanding | 62.48 | |||||
Days Payable | 107.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.62 | |||||
Forward Dividend Yield % | 1.62 | |||||
5-Year Yield-on-Cost % | 1.54 | |||||
Shareholder Yield % | 0.91 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.8 | |||||
Operating Margin % | -7.84 | |||||
Net Margin % | -8.41 | |||||
EBITDA Margin % | 0.98 | |||||
FCF Margin % | 8.33 | |||||
OCF Margin % | 13.32 | |||||
ROE % | -7.45 | |||||
ROA % | -6.19 | |||||
ROIC % | -11.28 | |||||
3-Year ROIIC % | 77.48 | |||||
ROC (Joel Greenblatt) % | -10.63 | |||||
ROCE % | -3.56 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 162.08 | |||||
PS Ratio | 3.42 | |||||
PB Ratio | 3.24 | |||||
Price-to-Tangible-Book | 3.18 | |||||
Price-to-Free-Cash-Flow | 41.34 | |||||
Price-to-Operating-Cash-Flow | 25.81 | |||||
EV-to-EBIT | -67.18 | |||||
EV-to-EBITDA | 290.26 | |||||
EV-to-Revenue | 2.82 | |||||
EV-to-FCF | 32.9 | |||||
Price-to-GF-Value | 0.6 | |||||
Price-to-Projected-FCF | 28.24 | |||||
| Price-to-Net-Current-Asset-Value | 4.22 | |||||
| Price-to-Net-Cash | 13.75 | |||||
Earnings Yield (Greenblatt) % | -1.48 | |||||
FCF Yield % | 2.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gentian Diagnostics AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 175.918 | ||
| EPS (TTM) (kr) | -0.97 | ||
| Beta | -0.0309 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.11 | ||
| Volatility % | 43.28 | ||
| 14-Day RSI | 49.7 | ||
| 14-Day ATR (kr) | 2.007331 | ||
| 20-Day SMA (kr) | 36.36 | ||
| 12-1 Month Momentum % | -39.97 | ||
| 52-Week Range (kr) | 33.5 - 64.2 | ||
| Shares Outstanding (Mil) | 15.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gentian Diagnostics AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gentian Diagnostics AS Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-20 | In 108 days | ||
| Third quarter earnings results for 2026 | 2026-10-20 | In 108 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-09 09:00 | In 6 days | ||
| Second quarter earnings results for 2026 | 2026-07-09 | In 5 days | ||
| First quarter earnings conference call for 2026 | 2026-05-06 09:00 | 44.80 (+6.41%) | ||
| NOK 0.600000 Cash Dividend | 2026-05-06 | 44.80 (+6.41%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 44.80 (+6.41%) | ||
| General meeting for 2025 | 2026-05-05 11:00 | 43.80 (-0.45%) | ||
| Annual report for 2026 | 2026-03-20 | 38.70 (-0.77%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-11 09:00 | 58.00 (+0.35%) |
Show
Entries
Gentian Diagnostics AS Frequently Asked Questions
What is Gentian Diagnostics AS(OSL:GENT)'s stock price today?
The current price of OSL:GENT is kr37.00. The 52 week high of OSL:GENT is kr64.20 and 52 week low is kr33.50.
When is next earnings date of Gentian Diagnostics AS(OSL:GENT)?
The next earnings date of Gentian Diagnostics AS(OSL:GENT) is 2026-07-09.
Does Gentian Diagnostics AS(OSL:GENT) pay dividends? If so, how much?
The Dividend Yield %  of Gentian Diagnostics AS(OSL:GENT) is 1.62% (As of Today), Highest Dividend Payout Ratio of Gentian Diagnostics AS(OSL:GENT) was 0.47. The lowest was 0.47. And the median was 0.47. The  Forward Dividend Yield % of Gentian Diagnostics AS(OSL:GENT) is 1.62%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Gentian Diagnostics AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers